Literature DB >> 8522631

Effective half-life in clinical pharmacology.

H Boxenbaum1, M Battle.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 8522631     DOI： 10.1002/j.1552-4604.1995.tb04117.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  32 in total

1.  Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Authors:  Christoph Beglinger; Ke Hu; Ying Wang; Emmanuel Bouillaud; Christelle Darstein; Yanfeng Wang; Pharis Mohideen
Journal:  Endocrine       Date:  2012-04-21       Impact factor: 3.633

2.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

3.  Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation.

Authors:  Anita Grover; Leslie Z Benet
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-04-16       Impact factor: 2.745

4.  Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.

Authors:  Sandeep Dutta; Ronald C Reed
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Authors:  Ping Chen; Adimoolam Narayanan; Benjamin Wu; Per Olsson Gisleskog; John P Gibbs; Andrew T Chow; Murad Melhem
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

6.  Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Authors:  Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-19       Impact factor: 2.205

7.  Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.

Authors:  Jerry Nedelman; Roland Fisch; Ke Hu; Ines Paule; Jocelyn Zhou
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

8.  Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.

Authors:  Dale Miles; Nelson L Jumbe; Steven Lacy; Linh Nguyen
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

9.  Characterization of AUCs from sparsely sampled populations in toxicology studies.

Authors:  S M Pai; S H Fettner; G Hajian; M N Cayen; V K Batra
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

10.  Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis.

Authors:  Dora Babu Madhura; Ashit Trivedi; Jiuyu Liu; Vincent A Boyd; Cynthia Jeffries; Vivian Loveless; Richard E Lee; Bernd Meibohm
Journal:  AAPS J       Date:  2016-03-16       Impact factor: 4.009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.